Published in Schizophr Bull on September 02, 2011
Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol (2014) 1.04
Effects of short-term inpatient treatment on sensitivity to a size contrast illusion in first-episode psychosis and multiple-episode schizophrenia. Front Psychol (2013) 0.95
The coherent organization of mental life depends on mechanisms for context-sensitive gain-control that are impaired in schizophrenia. Front Psychol (2013) 0.92
Deficient biological motion perception in schizophrenia: results from a motion noise paradigm. Front Psychol (2013) 0.90
Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci (2015) 0.87
Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med (2014) 0.86
Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin (2014) 0.85
An event-related potential examination of contour integration deficits in schizophrenia. Front Psychol (2013) 0.85
Role of visual integration in gaze perception and emotional intelligence in schizophrenia. Schizophr Bull (2013) 0.83
Comparison of psychophysical, electrophysiological, and fMRI assessment of visual contrast responses in patients with schizophrenia. Neuroimage (2012) 0.82
Visual sensory processing deficits in schizophrenia: is there anything to the magnocellular account? Schizophr Res (2012) 0.82
Prolonged temporal interaction for peripheral visual processing in schizophrenia: evidence from a three-flash illusion. Schizophr Res (2014) 0.80
Using model systems to understand errant plasticity mechanisms in psychiatric disorders. Nat Neurosci (2016) 0.80
Cortical contributions to impaired contour integration in schizophrenia. Neuropsychologia (2015) 0.79
Neuropsychological functions and visual contrast sensitivity in schizophrenia: the potential impact of comorbid posttraumatic stress disorder (PTSD). Front Psychol (2013) 0.79
Deficient cortical face-sensitive N170 responses and basic visual processing in schizophrenia. Schizophr Res (2015) 0.79
The Core Brain Region for Face Processing in Schizophrenia Lacks Face Selectivity. Schizophr Bull (2015) 0.78
Animal models and measures of perceptual processing in schizophrenia. Neurosci Biobehav Rev (2013) 0.78
Oscillatory underpinnings of mismatch negativity and their relationship with cognitive function in patients with schizophrenia. PLoS One (2013) 0.78
Atypical visual and somatosensory adaptation in schizophrenia-spectrum disorders. Transl Psychiatry (2016) 0.77
Auditory mismatch negativity and repetition suppression deficits in schizophrenia explained by irregular computation of prediction error. PLoS One (2015) 0.76
Maternal Systemic Interleukin-6 During Pregnancy Is Associated With Newborn Amygdala Phenotypes and Subsequent Behavior at 2 Years of Age. Biol Psychiatry (2017) 0.75
Effects of transcranial direct current stimulation on the auditory mismatch negativity response and working memory performance in schizophrenia: a pilot study. J Neural Transm (Vienna) (2017) 0.75
The analysis of visual motion: a comparison of neuronal and psychophysical performance. J Neurosci (1992) 9.58
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) (2001) 5.67
A direct quantitative relationship between the functional properties of human and macaque V5. Nat Neurosci (2000) 4.85
Sensorimotor adaptation in speech production. Science (1998) 4.57
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) (2001) 4.52
Visual input evokes transient and strong shunting inhibition in visual cortical neurons. Nature (1998) 3.30
Towards a neuropsychology of schizophrenia. Br J Psychiatry (1988) 2.89
A specific and enduring improvement in visual motion discrimination. Science (1982) 2.73
Corollary discharge across the animal kingdom. Nat Rev Neurosci (2008) 2.71
Sensory-motor interaction in the primate auditory cortex during self-initiated vocalizations. J Neurophysiol (2002) 2.42
Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res (2005) 2.41
Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch Gen Psychiatry (2005) 2.25
Visual processing in monkey extrastriate cortex. Annu Rev Neurosci (1987) 2.21
Motion perception in schizophrenia. Arch Gen Psychiatry (1999) 2.20
Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. Arch Gen Psychiatry (2002) 2.18
Visual perception and its impairment in schizophrenia. Biol Psychiatry (2008) 2.11
Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05
Efference copy and corollary discharge: implications for thinking and its disorders. Schizophr Bull (1978) 1.98
Development and plasticity of cortical processing architectures. Science (1995) 1.96
Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry (2005) 1.87
Contour saliency in primary visual cortex. Neuron (2006) 1.78
Relationship of imprecise corollary discharge in schizophrenia to auditory hallucinations. Arch Gen Psychiatry (2007) 1.66
Transformation of shape information in the ventral pathway. Curr Opin Neurobiol (2007) 1.64
Synch before you speak: auditory hallucinations in schizophrenia. Am J Psychiatry (2007) 1.55
How the contrast gain control modifies the frequency responses of cat retinal ganglion cells. J Physiol (1981) 1.53
Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clin Neurophysiol (2000) 1.52
Sensory contributions to impaired emotion processing in schizophrenia. Schizophr Bull (2009) 1.48
Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull (2008) 1.32
Stimulus deviance and evoked potentials. Biol Psychol (1982) 1.30
Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res (2003) 1.17
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. Int J Neuropsychopharmacol (2006) 1.15
An fMRI examination of visual integration in schizophrenia. J Integr Neurosci (2009) 1.15
Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res (2007) 1.11
Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters: implications for theories of cortical dysfunction. Schizophr Res (1999) 1.10
A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology (Berl) (2006) 1.10
Primary and secondary neural networks of auditory prepulse inhibition: a functional magnetic resonance imaging study of sensorimotor gating of the human acoustic startle response. Eur J Neurosci (2007) 1.07
Luminance-contrast mechanisms in humans: visual evoked potentials and a nonlinear model. Vision Res (2006) 1.06
Differential activation patterns of occipital and prefrontal cortices during motion processing: evidence from normal and schizophrenic brains. Cogn Affect Behav Neurosci (2008) 1.05
Visual processing, social cognition and functional outcome in schizophrenia. Psychiatry Res (2010) 0.99
Assessing corollary discharge in humans using noninvasive neurophysiological methods. Nat Protoc (2010) 0.98
Defining the units of competition: influences of perceptual organization on competitive interactions in human visual cortex. J Cogn Neurosci (2010) 0.94
Electrophysiology meets fMRI: neural correlates of the startle reflex assessed by simultaneous EMG-fMRI data acquisition. Hum Brain Mapp (2010) 0.92
Imaging biomarkers for treatment development for impaired cognition: report of the sixth CNTRICS meeting: Biomarkers recommended for further development. Schizophr Bull (2011) 0.90
Psilocybin impairs high-level but not low-level motion perception. Neuroreport (2004) 0.87
Attentional modulation of perceptual organisation in schizophrenia. Cogn Neuropsychiatry (2009) 0.87
Coherent Infomax as a computational goal for neural systems. Bull Math Biol (2010) 0.86
Improved test-retest reliability of 50-ms paired-click auditory gating using magnetoencephalography source modeling. Psychophysiology (2007) 0.85
Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell (2006) 11.38
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull (2005) 4.66
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res (2007) 3.79
Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol (2012) 3.49
JMJD6 is a histone arginine demethylase. Science (2007) 3.48
Habituation revisited: an updated and revised description of the behavioral characteristics of habituation. Neurobiol Learn Mem (2008) 3.23
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Identification of lysine succinylation as a new post-translational modification. Nat Chem Biol (2010) 2.87
The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics (2011) 2.83
Dynamic activity of lipid droplets: protein phosphorylation and GTP-mediated protein translocation. J Proteome Res (2007) 2.76
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Biosocial pathways to functional outcome in schizophrenia. Schizophr Res (2005) 2.65
Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. Am J Respir Crit Care Med (2011) 2.64
Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour. CMAJ (2007) 2.60
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Association between gaseous ambient air pollutants and adverse pregnancy outcomes in Vancouver, Canada. Environ Health Perspect (2003) 2.55
Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull (2006) 2.53
Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. Behav Brain Sci (2003) 2.51
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am J Psychiatry (2006) 2.42
Effect of weight reduction on respiratory function and airway reactivity in obese women. Chest (2004) 2.35
Dysregulation of working memory and default-mode networks in schizophrenia using independent component analysis, an fBIRN and MCIC study. Hum Brain Mapp (2009) 2.28
Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry (2013) 2.24
SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways. Mol Cell (2013) 2.17
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Visual perception and its impairment in schizophrenia. Biol Psychiatry (2008) 2.11
Acetylation of yeast AMPK controls intrinsic aging independently of caloric restriction. Cell (2011) 2.10
Nonconscious and conscious color priming in schizophrenia. J Psychiatr Res (2012) 2.08
An intimate collaboration between peroxisomes and lipid bodies. J Cell Biol (2006) 2.04
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Fine-tuning of auditory cortex during speech production. Psychophysiology (2005) 1.94
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry (2006) 1.93
Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull (2003) 1.89
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. J Magn Reson Imaging (2012) 1.86
Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med (2007) 1.85
Affective traits in schizophrenia and schizotypy. Schizophr Bull (2008) 1.81
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
Comparison of time series and case-crossover analyses of air pollution and hospital admission data. Int J Epidemiol (2003) 1.79
Beta toxin is essential for the intestinal virulence of Clostridium perfringens type C disease isolate CN3685 in a rabbit ileal loop model. Mol Microbiol (2008) 1.78
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry (2004) 1.72
Does anhedonia in schizophrenia reflect faulty memory for subjectively experienced emotions? J Abnorm Psychol (2006) 1.71
Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol (2005) 1.70
Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother (2006) 1.69
A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry (2009) 1.69
From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry (2012) 1.68
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell (2006) 1.67
Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res (2006) 1.67
Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry (2012) 1.67
Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. Schizophr Bull (2011) 1.67
Relationship of imprecise corollary discharge in schizophrenia to auditory hallucinations. Arch Gen Psychiatry (2007) 1.66
Gender-related differences in the association between socioeconomic status and self-reported diabetes. Int J Epidemiol (2003) 1.61
The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res (2004) 1.59
Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. Proc Natl Acad Sci U S A (2005) 1.59
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest (2003) 1.58
The influence of ambient coarse particulate matter on asthma hospitalization in children: case-crossover and time-series analyses. Environ Health Perspect (2002) 1.57
Brain regions associated with psychological pain: implications for a neural network and its relationship to physical pain. Brain Imaging Behav (2013) 1.56
Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr Bull (2011) 1.56
Increased risk of depression in COPD patients with higher education and income. Chron Respir Dis (2005) 1.56
Perceptual grouping in disorganized schizophrenia. Psychiatry Res (2006) 1.54
How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull (2007) 1.53
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Anatomy of an error: ERP and fMRI. Biol Psychol (2003) 1.52
Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine (2010) 1.51
Social cognition in psychosis: multidimensional structure, clinical correlates, and relationship with functional outcome. Schizophr Res (2010) 1.50
Response-monitoring dysfunction in schizophrenia: an event-related brain potential study. J Abnorm Psychol (2002) 1.50
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry (2003) 1.48
Perceptual organization in schizophrenia spectrum disorders: empirical research and theoretical implications. Psychol Bull (2005) 1.47
Histories of childhood maltreatment in schizophrenia: relationships with premorbid functioning, symptomatology, and cognitive deficits. Schizophr Res (2005) 1.46
Effects of intracellular superoxide removal at acupoints with TAT-SOD on obesity. Free Radic Biol Med (2011) 1.46
An overview of the association between allergy and cancer. Int J Cancer (2006) 1.45
Retracted catena-Poly[[[diaqua-thulium(III)]-μ-6-carboxy-nicotinato-μ-pyridine-2,5-di-carboxyl-ato] dihydrate]. Acta Crystallogr Sect E Struct Rep Online (2009) 1.44
Isolation and characterization of a novel DNA methyltransferase complex linking DNMT3B with components of the mitotic chromosome condensation machinery. Nucleic Acids Res (2004) 1.44
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients. Schizophr Res (2008) 1.41
Fine particulate air pollution and all-cause mortality within the Harvard Six-Cities Study: variations in risk by period of exposure. Ann Epidemiol (2002) 1.39
Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium. Schizophr Bull (2008) 1.39
Autophosphorylation-dependent activation of human Mps1 is required for the spindle checkpoint. Proc Natl Acad Sci U S A (2007) 1.39
Comprehensive profiling of protein lysine acetylation in Escherichia coli. J Proteome Res (2013) 1.39
Studies in genetically modified mice suggest novel mechanisms of mood regulation. Biol Psychiatry (2010) 1.38
Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull (2011) 1.38
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull (2010) 1.36
Kinetics of non-structural protein 1, IgM and IgG antibodies in dengue type 1 primary infection. Virol J (2011) 1.35
Molecular characterization of propionyllysines in non-histone proteins. Mol Cell Proteomics (2008) 1.33
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry (2004) 1.33
Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology (2006) 1.33
A clean, more efficient method for in-solution digestion of protein mixtures without detergent or urea. J Proteome Res (2006) 1.33
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry (2007) 1.32
Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull (2008) 1.32
The bZIP transcription factor MoAP1 mediates the oxidative stress response and is critical for pathogenicity of the rice blast fungus Magnaporthe oryzae. PLoS Pathog (2011) 1.32